Tags

Type your tag names separated by a space and hit enter

An emerging treatment: Topical ivermectin for papulopustular rosacea.
J Dermatolog Treat. 2015; 26(4):379-80.JD

Abstract

Ivermectin shows broad-spectrum anti-parasitic activity. It kills the Demodex mites that reside in the pilosebaceous units of patients with papulopustular rosacea. Ivermectin also has anti-inflammatory effects, it decreases cellular and humoral immune responses. Inflammatory mechanisms appear to play a dominant role in the development of rosacea inflammatory lesions. Additionally, there is some evidence that it shows antimicrobial activity against Myobacterium tuberculosis and Chlamydia trachomatis. The recent clinical studies of ivermectin on rosacea show that it was superior to vehicle in reducing inflammatory lesion counts, and its tolerability was excellent. Ivermectin displays antimicrobial, antiparasitic, antibacterial, and anti-inflammatory activities.

Authors+Show Affiliations

Department of Dermatology, Wake Forest School of Medicine , Winston-Salem, NC , USA.No affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

25424053

Citation

Abokwidir, Manal, and Alan B. Fleischer. "An Emerging Treatment: Topical Ivermectin for Papulopustular Rosacea." The Journal of Dermatological Treatment, vol. 26, no. 4, 2015, pp. 379-80.
Abokwidir M, Fleischer AB. An emerging treatment: Topical ivermectin for papulopustular rosacea. J Dermatolog Treat. 2015;26(4):379-80.
Abokwidir, M., & Fleischer, A. B. (2015). An emerging treatment: Topical ivermectin for papulopustular rosacea. The Journal of Dermatological Treatment, 26(4), 379-80. https://doi.org/10.3109/09546634.2014.991672
Abokwidir M, Fleischer AB. An Emerging Treatment: Topical Ivermectin for Papulopustular Rosacea. J Dermatolog Treat. 2015;26(4):379-80. PubMed PMID: 25424053.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - An emerging treatment: Topical ivermectin for papulopustular rosacea. AU - Abokwidir,Manal, AU - Fleischer,Alan B, Y1 - 2015/01/30/ PY - 2014/11/27/entrez PY - 2014/11/27/pubmed PY - 2016/2/19/medline KW - Avermectin KW - ivermectin KW - mechanism of action KW - papulopustular rosacea SP - 379 EP - 80 JF - The Journal of dermatological treatment JO - J Dermatolog Treat VL - 26 IS - 4 N2 - Ivermectin shows broad-spectrum anti-parasitic activity. It kills the Demodex mites that reside in the pilosebaceous units of patients with papulopustular rosacea. Ivermectin also has anti-inflammatory effects, it decreases cellular and humoral immune responses. Inflammatory mechanisms appear to play a dominant role in the development of rosacea inflammatory lesions. Additionally, there is some evidence that it shows antimicrobial activity against Myobacterium tuberculosis and Chlamydia trachomatis. The recent clinical studies of ivermectin on rosacea show that it was superior to vehicle in reducing inflammatory lesion counts, and its tolerability was excellent. Ivermectin displays antimicrobial, antiparasitic, antibacterial, and anti-inflammatory activities. SN - 1471-1753 UR - https://brain.unboundmedicine.com/medline/citation/25424053/An_emerging_treatment:_Topical_ivermectin_for_papulopustular_rosacea_ L2 - https://www.tandfonline.com/doi/full/10.3109/09546634.2014.991672 DB - PRIME DP - Unbound Medicine ER -